skip links

Media Inquiries

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]
Sort by Year
May 25, 2022

Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022

May 9, 2022

Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

May 5, 2022

Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

April 21, 2022

Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call

March 2, 2022

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

February 17, 2022

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021

February 3, 2022

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call

January 10, 2022

Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance

January 5, 2022

Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

December 1, 2021

Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

November 4, 2021

Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update

November 4, 2021

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

October 25, 2021

More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021

October 21, 2021

Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call

September 2, 2021

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences